Daidzein, R-(+)equol and S-(-)equol inhibit the invasion of MDA-MB-231 breast cancer cells potentially via the down-regulation of matrix metalloproteinase-2

European Journal of Nutrition

Volumn 53, Issue 1, 2014, Pages 345-350

  Magee, Pamela J ^a   Allsopp, Philip ^a   Samaletdin, Adile ^b   Rowland, Ian R ^c  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF READING   (United Kingdom)

Author keywords

Breast cancer; Daidzein; R equol; S equol; Soy isoflavone

Indexed keywords

BREAST NEOPLASMS; CELL LINE, TUMOR; DOWN-REGULATION; EQUOL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOFLAVONES; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; RNA, MESSENGER; SOYBEANS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 84895077403     PISSN: 14366207     EISSN: 14366215     Source Type: Journal    
DOI: 10.1007/s00394-013-0520-z     Document Type: Article

References (31)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2008) GLOBOCAN 2008, Cancer incidence and mortality worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr (accessed October 2012)
2. Magee PJ, Rowland IR (2004) Phyto-oestrogens, their mechanism of action: current evidence for a role in breast and prostate cancer. Br J Nutr 91:513-531
3. Steiner C, Arnould S, Scalbert A, Manach C (2008) Isoflavones and the prevention of breast and prostate cancer: new perspectives opened by nutrigenomics. Br J Nutr 99:ES78-ES108
4. Yuan J-P, Wang J-H, Liu X (2007) Metabolism of dietary soy isoflavones to equol by human intestinal microflora - implications for health. Mol Nutr Food Res 51:765-781
5. Setchell KDR, Clerici C, Lephart E, Cole SJ, Heenan C, et al. (2005) S-equol, a potent ligand for estrogen receptor β, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr 81:1072-1079
6. Lampe JW, Karr SC, Hutchins AM, Slavin JL (1998) Urinary equol excretion with a soy challenge: influence of habitual diet. Proc Soc Exp Biol Med 217:335-339
7. Rowland I, Wiseman H, Sanders TAB, Adlercreutz H, Bowey EA (2000) Interindividual variation in metabolism of soy isoflavones and lignans: influence of habitual diet on equol production by the gut microflora. Nutr Cancer 36:27-32
8. Setchell KDR, Cole SJ (2006) Method of defining equol-producer status and its frequency among vegetarians. J Nutr 136:2188-2193
9. Radisky ES, Radisky DC (2010) Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia 15:201-212
10. Xu X, Wang Y, Chen Z, Sternlicht M, Hidalgo M, Steffensen B (2005) Matrix metalloproteinase-2 contributes to cancer cell migration on collagen. Cancer Res 65:130-136
11. Deryugina E, Luo G, Reisfeld R, Bourdon M, Strongin A (1997) Tumor cell invasion through matrigel is regulated by activated matrix metalloproteinase-2. Anticancer Res 17:3201-3210
12. Balduyck M, Zerimech F, Gouyer V, Lemaire R, Hemon B, Grard G, Thiebaut C, Lemaire V, Dacquembronne E, Duhem T, Lebrun A, Dejonghe M, Huet G (2000) Specific expression of matrix metalloproteinases 1, 3, 9 and 13 associated with invasiveness of breast cancer cells in vitro. Clin Exp Metastasis 18:171-178
13. Azzam H, Arand G, Lippman M, Thompson E (1993) Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 production. J Natl Cancer Inst 85:1758-1764
14. Ranogajec I, Jakic-Razumovic J, Puzovic V, Gabrilovac J (2011) Prognostic value of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) and aminopeptidase N/CD13 in breast cancer patients. Med Oncol May 25 [Epub ahead of print]
15. Leppa S, Saarto T, Vehmanen L, Blomqvist C, Elomaa I (2004) A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma. Clin Cancer Res 10:1057-1063
16. Rocca GL, Pucci-Minafra I, Marrazzo A, Taormina P, Minafra S (2004) Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera. Br J Cancer 90:1414-1421
17. Shao Z, Wu J, Shen Z, Barsky S (1998) Genistein exerts multiple suppressive effects on human breast carcinoma cells. Cancer Res 58:4851-4857
18. Magee PJ, McGlynn H, Rowland IR (2004) Differential effects of isoflavones and lignans on invasiveness of MDA-MB-231 breast cancer cells in vitro. Cancer Lett 208:35-41
19. Magee PJ, Raschke M, Steiner C, Duffin JG, Pool-Zobel BL, Jokela T, Wahala K, Rowland IR (2006) Equol: A comparison of the effects of the racemic compound with that of the purified S-enantiomer on the growth, invasion, and DNA integrity of breast and prostate cells in vitro. Nutr Cancer 54:232-242
20. Kousidou OC, Mitropoulou TN, Roussidis AE, Kletsas D, Theocharis AD, Karamanos NK (2005) Genistein suppresses the invasive potential of human breast cancer cells through transcriptional regulation of metalloproteinases and their tissue inhibitors. Int J Oncol 26:1101-1109
21. Cailleau R, Young R, Olive M, Reeves W (1974) Breast tumour cell lines from pleural effusions. J Natl Cancer Inst 53:661-674
22. Mossman T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63
23. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29(9):e45
24. Yang Z, Strickland D, Bornstein P (2001) Extracellular matrix metalloproteinase 2 levels are regulated by the low density lipoprotein-related scavenger receptor and thrombospondin 2. J Biol Chem 276:8403-8408
25. (2011) Anti-invasion effects of R- and S-enantiomers of equol on prostate cancer PC3, DU145 cells. Wei Sheng Yan Jiu 40:423-430 (article in Chinese; no authors listed)
26. Zheng W, Zhang Y, Ma D, Shi Y, Liu C, Wang P (2012) (±) Equol inhibits invasion in prostate cancer DU145 cells possibly via down-regulation of matrix metalloproteinase-9, matrix metalloproteinase-2 and urokinase-type plasminogen activator by antioxidant activity. J Clin Biochem Nutr 51:61-67
27. Valachovicova T, Slivova V, Bergman H, Shuherk J, Sliva D (2004) Soy isoflavones suppress invasiveness of breast cancer cells by the inhibition of NF-kB/AP-1-dependent and -independent pathways. Int J Oncol 25:1389-1395
28. Brown NM, Belles CA, Lindley SL, Zimmer-Nechemias LD, Zhao X, Witte DP, Kim M-O, Setchell KDR (2010) The chemopreventive action of equol enantiomers in a chemically induced animal model of breast cancer. Carcinogenesis 31:886-893
29. Maubach J, Depypere HT, Goeman J, Van Der Eycken J, Heyerick A, Bracke ME, Blondeel P, De Keukeleire D (2004) Distribution of soy-derived phytoestrogens in human breast tissue and biological fluids. Obstet Gynecol 103:892-898
30. Bolca S, Urpi-Sarda M, Blondeel P, Roche N, Vanhaecke L, Possemiers S, Al-Maharik N, Botting N, De Keukeleire D, Bracke M, Heyerick A, Manach C, Depypere H (2010) Disposition of soy isoflavones in normal human breast tissue. Am J Clin Nutr 91:976-984
31. Setchell KDR, Brown NM, Zhao X, Lindley SL, Heubi JE, King EC, Messina MJ (2011) Soy isoflavone phase II metabolism differs between rodents and humans: implications for the effect on breast cancer risk. Am J Clin Nutr 94:1284-1294